hVIVO launches hMPV Challenge Model to fast-track treatments
7th April 2025
hVIVO introduces groundbreaking hMPV challenge model to hasten vaccine and therapy development against respiratory pathogen. Learn more here.
hVIVO introduces groundbreaking hMPV challenge model to hasten vaccine and therapy development against respiratory pathogen. Learn more here.
hVIVO uncovers rare subclinical myocarditis cases in RSV clinical trials, showcasing the power of human challenge models for early signal detection in drug development.
One Health Group advances its expansion plans with a new surgical hub, bolstered by a successful AIM market debut and strong financial performance.
Retired engineer Keith Davies shares his journey from routine blood test to beating prostate cancer. Early detection is key.
Poolbeg Pharma is a cutting-edge biotech company with high-value therapeutic programmes and AI-led drug discovery, appealing to forward-thinking investors.
Discover how Venn Life Sciences navigated complex regulatory and technical challenges to help a Japanese biotech company scale production for US clinical trials seamlessly.
In a sector where timelines can stretch over decades and budgets run into billions, hVIVO is rewriting the rules—delivering clinical insight in a fraction of the time and attracting heavyweight
Discover how digital innovation in the pharmaceutical sector is revolutionizing drug development, accelerating treatments, and transforming healthcare.
Discover how hVIVO’s hMPV challenge model is revolutionizing vaccine testing with high infection rates and accurate results. Learn more here.
One Health Group’s successful AIM listing and capital injection of £7.8 million signal a new era in delivering cutting-edge surgical hubs aligned with NHS priorities.
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
